Article Details

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 ...

Retrieved on: 2022-12-27 22:26:52

Tags for this article:

Click the tags to see associated articles and topics

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 .... View article details on hiswai:

Excerpt

“GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with ...

Article found on: www.gilead.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up